Brain

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...

PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience

Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting

- MDNA11’s selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation...

Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 (GLOBE...

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala’

Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE)...

ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...

error: Content is protected !!